The anticancer agent methyl jasmonate induces activation of stress-regulated c-Jun N-terminal kinase and p38 protein kinase in human lymphoid cells.
Rotem
R
R
Fingrut
O
O
Moskovitz
J
J
Flescher
E
E
D000085:Acetates / Q000494:pharmacology*; D001483:Base Sequence; D001665:Binding Sites; D003513:Cycloheximide / Q000494:pharmacology; D003517:Cyclopentanes / Q000494:pharmacology*; D003609:Dactinomycin / Q000494:pharmacology; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases; D007700:Kinetics; D007945:Leukemia, Lymphoid; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D009838:Oligodeoxyribonucleotides / Q000378:metabolism; D054883:Oxylipins; D010766:Phosphorylation; D010937:Plant Growth Regulators / Q000494:pharmacology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D018808:Transcription Factor AP-1 / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D048051:p38 Mitogen-Activated Protein Kinases
D000085:Acetates; D003517:Cyclopentanes; D009838:Oligodeoxyribonucleotides; D054883:Oxylipins; D010937:Plant Growth Regulators; D011500:Protein Synthesis Inhibitors; D018808:Transcription Factor AP-1; D003609:Dactinomycin; C072239:methyl jasmonate; D003513:Cycloheximide; D048031:JNK Mitogen-Activated Protein Kinases; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases